American Well Corporation (AMWL) Bundle
Understanding American Well Corporation (AMWL) Revenue Streams
Understanding American Well Corporation’s Revenue Streams
Primary Revenue Sources
- Subscription Revenue: $26.2 million for the three months ended September 30, 2024, compared to $28.4 million for the same period in 2023.
- Visit Revenue: Remained consistent with a slight increase due to special program visits.
- Other Revenue: Increased by $0.9 million primarily from marketing revenue with strategic customers.
Year-over-Year Revenue Growth Rate
| Period | Total Revenue | Year-over-Year Change (%) |
|---|---|---|
| Q3 2024 | $61.046 million | -1.42% |
| Q3 2023 | $61.922 million | N/A |
| 9 Months Ended September 30, 2024 | $183.358 million | -2.68% |
| 9 Months Ended September 30, 2023 | $188.370 million | N/A |
Contribution of Different Business Segments to Overall Revenue
- Health Systems: Significant revenue from enterprise platform use.
- Health Plans: Recurring subscription fees based on member access and additional service fees.
- Government Healthcare Services: Tailored solutions contributing to revenue growth.
Analysis of Significant Changes in Revenue Streams
- Subscription revenue declined by $6.5 million for the nine months ended September 30, 2024, primarily due to customer churn during re-platforming.
- Visit revenue remained stable, offsetting declines in specialty visits with increases in special program visits.
- Overall, total revenue decreased by 3.20% for the nine months ended September 30, 2024, compared to the same period in 2023.
A Deep Dive into American Well Corporation (AMWL) Profitability
Profitability Metrics
Analyzing the profitability metrics of the company reveals significant insights into its financial health. Below are the key profitability metrics including gross profit, operating profit, and net profit margins.
Gross Profit, Operating Profit, and Net Profit Margins
For the three months ended September 30, 2024, the company's revenue was $61,046,000 with a cost of revenue of $38,352,000, resulting in a gross profit of $22,694,000. The gross margin can be calculated as follows:
- Gross Margin = (Gross Profit / Revenue) × 100 = (22,694 / 61,046) × 100 = 37.12%
The operating loss for the same period was $47,370,000, leading to an operating margin of:
- Operating Margin = (Operating Loss / Revenue) × 100 = (-47,370 / 61,046) × 100 = -77.64%
For the nine months ended September 30, 2024, total revenue was $183,358,000 with total costs and operating expenses of $358,136,000.
- Net Loss for the nine months was $168,069,000.
- Net Loss Margin = (Net Loss / Revenue) × 100 = (-168,069 / 183,358) × 100 = -91.70%
Trends in Profitability Over Time
Comparing the profitability metrics over the previous year, the company reported:
- Gross Profit for Q3 2023: $22,694,000 (Q3 2024: $22,694,000) - No change.
- Operating Loss for Q3 2023: $143,360,000 (Q3 2024: $47,370,000) - Improvement of $95,990,000.
- Net Loss for Q3 2023: $137,104,000 (Q3 2024: $44,041,000) - Improvement of $93,063,000.
Comparison of Profitability Ratios with Industry Averages
Industry averages for similar companies in the digital healthcare sector typically show gross margins around 60% and net margins around -10% to -30%. The company currently shows:
- Gross Margin: 37.12%
- Net Margin: -91.70%
This indicates that the company is currently below industry averages, which may suggest inefficiencies or challenges in scaling operations effectively.
Analysis of Operational Efficiency
Operational efficiency can be assessed through various metrics, including cost management and gross margin trends. The total costs and operating expenses for the nine months ended September 30, 2024, were significantly lower than the previous year:
| Period | Total Revenue | Total Costs and Operating Expenses | Net Loss |
|---|---|---|---|
| Q3 2023 | $188,370,000 | $823,558,000 | $629,128,000 |
| Q3 2024 | $183,358,000 | $358,136,000 | $168,069,000 |
This reduction in costs by approximately $465,422,000 shows significant improvements in cost management, positively impacting operational efficiency.
Debt vs. Equity: How American Well Corporation (AMWL) Finances Its Growth
Debt vs. Equity: How American Well Corporation Finances Its Growth
As of September 30, 2024, American Well Corporation reported a total debt of $0, indicating it has no outstanding long-term or short-term debt. This places the company in a unique position compared to many peers in the healthcare technology sector which often rely on debt financing for growth.
The debt-to-equity ratio is a critical measure for assessing financial leverage. In this case, the company's debt-to-equity ratio stands at 0, which is significantly lower than the industry average of approximately 0.5 to 1.0. This reflects a conservative approach to financing and a reliance on equity rather than debt.
Recent activity indicates that the company has not issued any new debt instruments or engaged in refinancing during the latest reporting period. Consequently, the credit rating remains unaffected and continues to reflect a stable outlook, given the absence of debt obligations.
The company balances its financing strategy through equity funding, primarily derived from stock issuances. As of September 30, 2024, the total stockholders' equity was reported at $336.7 million, with accumulated deficits amounting to $1.9 billion. This indicates that while the company has substantial equity, it also carries significant accumulated losses that will need to be addressed for future profitability.
| Financial Metric | Value |
|---|---|
| Total Debt | $0 |
| Debt-to-Equity Ratio | 0 |
| Industry Average Debt-to-Equity Ratio | 0.5 - 1.0 |
| Total Stockholders' Equity | $336.7 million |
| Accumulated Deficits | $1.9 billion |
This financing approach allows the company to mitigate financial risk associated with debt repayments while maintaining flexibility for future capital needs. However, the reliance on equity funding may dilute existing shareholders' interests, particularly if additional equity financing is required to support growth initiatives.
Assessing American Well Corporation (AMWL) Liquidity
Assessing American Well Corporation's Liquidity
Current Assets as of September 30, 2024, totaled $356.9 million, down from $449.6 million as of December 31, 2023. This decline is primarily attributed to a decrease in cash and cash equivalents from $372.0 million to $244.6 million.
Current Liabilities increased from $93.8 million to $122.2 million during the same period, resulting in a working capital of $234.7 million as of September 30, 2024.
| Item | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $244.6 million | $372.0 million |
| Accounts Receivable | $89.3 million | $54.1 million |
| Inventories | $4.8 million | $6.7 million |
| Total Current Assets | $356.9 million | $449.6 million |
| Total Current Liabilities | $122.2 million | $93.8 million |
| Working Capital | $234.7 million | $355.8 million |
Current and Quick Ratios
The current ratio as of September 30, 2024, is calculated as follows:
Current Ratio = Current Assets / Current Liabilities = $356.9 million / $122.2 million = 2.92
The quick ratio is calculated excluding inventories:
Quick Ratio = (Current Assets - Inventories) / Current Liabilities = ($356.9 million - $4.8 million) / $122.2 million = 2.87
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow activities are summarized below:
| Cash Flow Activity | 2024 | 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | $(113.9 million) | $(106.8 million) |
| Net Cash Used in Investing Activities | $(14.5 million) | $(113.5 million) |
| Net Cash Provided by Financing Activities | $1.4 million | $2.1 million |
| Total | $(127.0 million) | $(218.1 million) |
Liquidity Concerns and Strengths
As of September 30, 2024, the company reported an accumulated deficit of $1.92 billion and a total net loss of $168.1 million for the nine months ended September 30, 2024. Despite the ongoing losses, the company maintains a strong cash position with $244.6 million in cash and cash equivalents, which is projected to cover operational needs for at least the next 12 months.
There are no outstanding debts as of September 30, 2024, which enhances the company’s liquidity profile. However, the significant losses and decline in cash reserves raise potential liquidity concerns that need to be monitored closely.
Is American Well Corporation (AMWL) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will examine key financial metrics including the price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio.
Price-to-Earnings (P/E) Ratio
The trailing twelve months (TTM) P/E ratio is currently N/A due to the company reporting a net loss.
Price-to-Book (P/B) Ratio
The current P/B ratio stands at 0.15, calculated based on a book value of $1,923.3 million and shares outstanding of 15,287,409.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is also N/A as the company has reported negative EBITDA for the last twelve months.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated significantly:
- 12-month high: $4.25
- 12-month low: $0.88
- Current stock price (as of October 2024): $1.25
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0%.
Analyst Consensus
According to recent analyst reports, the consensus rating on the stock is Hold, with a target price estimate averaging around $1.80.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 0.15 |
| EV/EBITDA Ratio | N/A |
| 12-Month High Price | $4.25 |
| 12-Month Low Price | $0.88 |
| Current Stock Price | $1.25 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
| Average Target Price | $1.80 |
In summary, the company shows a low P/B ratio, no dividend payments, and a volatile stock price performance with a current analyst consensus of Hold.
Key Risks Facing American Well Corporation (AMWL)
Key Risks Facing American Well Corporation
The financial health of American Well Corporation is influenced by various internal and external risks. Understanding these risks is crucial for investors seeking to navigate the complexities of the healthcare technology sector.
Industry Competition
The telehealth industry is highly competitive, with numerous players vying for market share. As of September 30, 2024, the company reported a net loss attributable to its operations of $43.5 million, a significant reduction from $136.4 million during the same period in 2023. This improvement reflects ongoing competitive pressures but also indicates challenges in maintaining market position amidst rapidly evolving technologies and consumer preferences.
Regulatory Changes
Regulatory changes pose a substantial risk to the company. The healthcare sector is subject to stringent regulations that can impact operational capabilities and profitability. For instance, the company has no debt as of September 30, 2024, which may provide some flexibility in managing regulatory compliance costs. However, the evolving landscape of healthcare regulations can lead to increased operational costs and require strategic adjustments.
Market Conditions
Market conditions, including economic downturns and shifts in healthcare spending, can significantly affect revenue streams. The company reported a decline in subscription revenue by $2.2 million in Q3 2024 due to customer churn during a re-platforming phase. This indicates vulnerability to market dynamics that may influence customer retention and acquisition.
Operational Risks
Operational risks are evident from the company's recent earnings reports. For the nine months ended September 30, 2024, the total costs and operating expenses amounted to $358.1 million, a decrease of 57% compared to the previous year. While cost reductions are beneficial, they may also reflect challenges in scaling operations effectively amidst a shifting business environment.
Financial Risks
Financial risks are underscored by the company’s continued operating losses. For the nine months ending September 30, 2024, the net loss was $168.1 million, down from $629.1 million in the prior year. This highlights ongoing financial instability, despite efforts to streamline costs and improve operational efficiency.
Mitigation Strategies
The company is implementing strategies to mitigate these risks. Cost-saving measures, including a reduction in employee-related costs by $6.3 million and a decrease in consulting expenses by $5.9 million, are designed to enhance financial stability. Additionally, the expansion of strategic partnerships and ongoing development of the Converge platform aim to bolster market presence and customer engagement.
| Risk Factor | Description | Impact |
|---|---|---|
| Industry Competition | High competition from numerous market players | Net loss of $43.5 million in Q3 2024 |
| Regulatory Changes | Impact of healthcare regulations on operations | No debt as of September 30, 2024 |
| Market Conditions | Economic factors affecting healthcare spending | Subscription revenue decline of $2.2 million |
| Operational Risks | Challenges in scaling operations effectively | Total operating expenses of $358.1 million |
| Financial Risks | Continued operating losses | Net loss of $168.1 million for nine months ended September 30, 2024 |
| Mitigation Strategies | Cost-saving measures and strategic partnerships | Employee-related costs reduced by $6.3 million |
Future Growth Prospects for American Well Corporation (AMWL)
Future Growth Prospects for American Well Corporation
Analysis of Key Growth Drivers
The primary growth drivers for the company include product innovations, strategic partnerships, and market expansions. The company has launched the Amwell Converge platform, which integrates various virtual care services. This platform has shown positive reception among key strategic accounts, contributing to a partial offset of subscription revenue declines due to customer churn.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total revenue was $183.4 million, down from $188.4 million for the same period in 2023. The company reported a net loss of $168.1 million for the nine months ended September 30, 2024, a decrease from $629.1 million in the same period in the previous year. Future projections indicate that as the company stabilizes its operations and enhances client relationships, revenue growth may resume in the coming fiscal periods.
Strategic Initiatives or Partnerships
The company has partnered with Cleveland Clinic to form a joint venture, CCAW, JV LLC, aimed at enhancing access to high-acuity care through digital delivery. The company has made capital contributions of $1.7 million in 2024 related to this venture. The expected benefits from this partnership could significantly enhance the company's service offerings and market reach.
Competitive Advantages Positioning the Company for Growth
The company leverages its established relationships with health systems, health plans, and government clients, which provide a robust foundation for growth. Its enterprise platform allows seamless integration of virtual care services, enhancing patient engagement and care delivery efficiency. The total cash and cash equivalents as of September 30, 2024, were $244.6 million, providing financial flexibility to pursue growth initiatives.
| Metric | 2024 (9 months) | 2023 (9 months) | Change |
|---|---|---|---|
| Total Revenue | $183.4 million | $188.4 million | -2.6% |
| Net Loss | $168.1 million | $629.1 million | -73.3% |
| Cash and Cash Equivalents | $244.6 million | $372.0 million | -34.3% |
| Capital Contribution to CCAW, JV LLC | $1.7 million | N/A | N/A |
The company continues to evaluate additional partnerships and acquisitions to enhance its competitive position and drive future growth. The successful implementation of its strategic initiatives is crucial for achieving sustainable revenue growth in the evolving digital healthcare landscape.
American Well Corporation (AMWL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- American Well Corporation (AMWL) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of American Well Corporation (AMWL)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View American Well Corporation (AMWL)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.